Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemochromatosis.

Paul C Adams1

  • 1Department of Medicine, University of Western Ontario, London Health Sciences Centre, University Campus, P.O. Box 5339, London, Ontario N6A 5A5, Canada.

Clinics in Liver Disease
|October 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Treatment of HFE<sup>C282Y</sup>-Linked Hemochromatosis.

Advances in experimental medicine and biology·2025
Same author

Association of <i>HFE</i> genotypes with hemochromatosis-related phenotypes in the All of Us research program.

Genetics in medicine open·2025
Same author

Diagnosis and Treatment of Hemochromatosis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Non-expressing homozygous C282Y carriers and haemochromatosis.

BMJ (Clinical research ed.)·2024
Same author

Concerns about new proposals for haemochromatosis screening - Authors' reply.

Lancet (London, England)·2023
Same author

Haemochromatosis.

Lancet (London, England)·2023
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Hemochromatosis is a common genetic disorder. Early genetic testing and phlebotomy treatment can prevent liver cirrhosis and ensure a normal life expectancy.

Area of Science:

  • Genetics
  • Hepatology
  • Internal Medicine

Background:

  • Hemochromatosis is a prevalent genetic disorder.
  • Clinical presentation varies widely, from asymptomatic cases to severe liver disease like cirrhosis.
  • Iron overload is the hallmark of this condition.

Purpose of the Study:

  • To highlight the significance of genetic discoveries in diagnosing hemochromatosis.
  • To emphasize the effectiveness of phlebotomy in managing the disease.
  • To inform about the potential for a normal life expectancy with timely intervention.

Main Methods:

  • Genetic testing for disease diagnosis.
  • Phlebotomy (blood removal) as a treatment modality.
  • Clinical observation of patient outcomes.

Related Experiment Videos

Main Results:

  • Genetic testing provides a reliable diagnostic tool.
  • Phlebotomy is an effective and straightforward treatment.
  • Treatment can prevent the progression to liver cirrhosis.

Conclusions:

  • Genetic hemochromatosis is manageable with early diagnosis and treatment.
  • Phlebotomy can normalize life expectancy by preventing severe complications.
  • Understanding the genetic basis has revolutionized patient care.